# Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive to Maximum Dose Metformin & Thiazolidinedione

> **NCT00044447** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 170 (actual)

## Conditions studied

- Diabetes Mellitus, Non-Insulin-Dependent

## Interventions

- **DRUG:** Glimepiride

## Key facts

- **NCT ID:** NCT00044447
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-05
- **Primary completion:** —
- **Final completion:** 2002-09
- **Target enrollment:** 170 (ACTUAL)
- **Last updated:** 2008-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00044447

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00044447, "Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients Unresponsive to Maximum Dose Metformin & Thiazolidinedione". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00044447. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*